Article info
Abstracts Accepted for Publication
Rheumatoid arthritis - other biologic treatment
AB0484 An Integrated Pharmacokinetic and Pharmacodynamic Approach to Guide Dose Selection of Namilumab, an Anti-GM-CSF Monoclonal Antibody, for Phase II Rheumatoid Arthritis Studies
Citation
AB0484 An Integrated Pharmacokinetic and Pharmacodynamic Approach to Guide Dose Selection of Namilumab, an Anti-GM-CSF Monoclonal Antibody, for Phase II Rheumatoid Arthritis Studies
Publication history
- First published June 9, 2015.
Online issue publication
April 13, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions